M. Zvarich

Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial.

N. Richard, A. Church, M. R. Maleki-Yazdi, 2014, Respiratory medicine.

Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.

C. Crim, J. Boscia, S. Siederer, 2012, Clinical therapeutics.

A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD

J. Bourbeau, A. Agustí, C. Crim, 2013, European Respiratory Journal.

Efficacy of combination fluticasone furoate/vilanterol (FF/VI) and salmeterol/fluticasone propionate (SFC) over 12 weeks in patients with COPD

J. Bourbeau, A. Agustí, C. Crim, 2012 .

Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee

Robert A Wise, Julie A. Anderson, R. Wise, 2007, Thorax.

ELLIPTA Versus DISKUS plus HandiHaler in COPD: A Randomized, Open-Label, Crossover Study in a Clinical Trial Setting.

E. Kerwin, S. Spangenthal, K. Collison, 2020, Chronic obstructive pulmonary diseases.

Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee

Julie A. Anderson, R. Wise, L. Mcgarvey, 2007, Thorax.